Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S (NYSE:NVO) after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.
BMO Capital Markets开始对丹麦制药商诺和诺德A/S（纽约证券交易所代码：NVO）进行报道，此前该公司凭借下一代著名的减肥和糖尿病药物获得了圣杯，引起了人们的兴趣。
The analyst writes that an in-depth analysis of the growing obesity and adjacent metabolic disease market suggests Eli Lilly And Co (NYSE:LLY) and Novo Nordisk will remain the two entrenched players in this duopoly.
该分析师写道，对日益增长的肥胖和邻近代谢性疾病市场的深入分析表明，礼来公司（纽约证券交易所代码：LLY）和诺和诺德仍将是这个双头垄断中的两个根深蒂固的参与者。
While other players are just entering the obesity landscape, Novo has been established as a leader since Wegovy's approval in 2021 (and Saxenda's approval in 2014).
尽管其他参与者刚刚进入肥胖领域，但自Wegovy于2021年获得批准（以及萨克森达在2014年获得批准）以来，Novo已成为领导者。
Related: Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors – After FDA, European Medicines Agency Says.
相关：欧洲药品管理局表示，Novo Nordisk/Eli Lilly的减肥药物不会导致自杀行为——仅次于FDA。
Novo Nordisk's decision to double down in obesity assets by developing therapeutics like CagriSema, GLP-1/GIPR agonists, and the new INV-202 has strengthened its pipeline in a market expected to grow to over $130 billion.
诺和诺德决定通过开发CagriSema、GLP-1/GIPR激动剂和新型 INV-202 等疗法来加倍增加肥胖资产，这加强了其在预计将增长至1,300亿美元以上的市场渠道。
In the near term, BMO looks to Phase 3 REDEFINE trial results for CagriSema in obesity and Phase 3 STRIDE and SOUL results for semaglutide in Peripheral arterial disease (PAD) and type-2 diabetes (T2D) with chronic kidney disease (CKD)/ cardiovascular disease (CVD), respectively, to push shares higher.
在短期内，BMO希望CagriSema治疗肥胖症的3期REDEFINE试验结果以及索玛鲁肽治疗外周动脉疾病（PAD）和2型糖尿病（T2D）伴有慢性肾脏病（CKD）/心血管疾病（CVD）的3期STRIDE和SOUL试验结果，以推动股价上涨。
Trials in secondary indications of obesity/T2D are expected to expand revenue and provide alternate paths to Medicare access.
肥胖/T2D 次要适应症的试验预计将扩大收入，并为获得医疗保险提供替代途径。
BMO is initiating with an Outperform rating and a price target of $163.
BMO最初的评级为跑赢大盘，目标股价为163美元。
Novo's growing strength is fueled by various factors, including robust manufacturing, clinical and patient data, diverse pipelines, and enhanced access support, reinforcing the optimistic outlook on Novo Nordisk.
Novo的实力不断增强是由各种因素推动的，包括强大的制造、临床和患者数据、多样化的渠道以及增强的准入支持，这强化了Novo Nordisk的乐观前景。
The company, along with Eli Lilly, dominates the market for incretin therapies, with demand rising steadily, especially after the approval of Wegovy.
该公司与礼来公司一起在肠促胰岛素疗法市场占据主导地位，需求稳步增长，尤其是在Wegovy获得批准之后。
Capacity limitations in the market, expected to persist until at least 2026, benefit both Novo and Lilly due to their substantial manufacturing capabilities, further bolstered by Catalent Inc (NYSE:CTLT).
市场产能限制预计至少将持续到2026年，这使诺沃和礼来均受益，这要归因于其强大的制造能力，加上Catalent Inc（纽约证券交易所代码：CTLT）的进一步支持。
These constraints fortify Novo Nordisk's competitive position, potentially impeding competitors even if they offer superior efficacy or tolerability.
这些限制巩固了诺和诺德的竞争地位，即使竞争对手具有卓越的疗效或耐受性，也有可能阻碍竞争对手。
Price Action: NVO shares are down 0.36% at $124.95 on the last check Friday.
价格走势：在周五的最后一次支票中，NVO股价下跌0.36％，至124.95美元。
Image Via Shutterstock
图片来自 Shutterstock